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 Lifestyle Changes 
 Non-alcoholic steatohepatitis (NASH) occurs with 
such frequency because it is the consequence of our physi-
ology being unable to adapt to our new living conditions, 
that is, the evolution selected for organisms able to store 
energy to survive famine. Nowadays, it is no longer a ne-
cessity for us to move to find food, as it would have been 
for our ancestors. We are constantly exposed to high en-
ergy and high caloric nutrients and overweight concerns a 
significant proportion of the population. Weight loss im-
proves transaminases. In a prospective, longitudinal co-
hort study, a correlation between weight changes and 
modification of transaminases was found  [1] . Patients who 
gained >5% of body weight had increased transaminases, 
whereas those who lost >5% of body weight saw an im-
provement in their transaminases. More than 5% weight 
reduction was also associated with a decrease in serum tri-
glycerides and fasting blood glucose, an increase in HDL 
cholesterol as well as decreased blood pressure. Harrison 
et al. [2] reported that losing  ≥ 5% of body weight over 9 
months was enough to improve insulin resistance as well 
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 Abstract 
 Non-alcoholic fatty liver disease (NAFLD) encompasses a 
spectrum of conditions from steatosis to cirrhosis and hepa-
tocellular carcinoma. Steatosis is a benign reversible condi-
tion, which does not need treatment. Cirrhosis and hepato-
cellular carcinoma are the end stages of any chronic liver dis-
ease and do not have etiology-specific treatments. In this 
chapter, we will review treatment options for non-alcoholic 
steatohepatitis, which is the progressive form of NAFLD. Ba-
sically there are 2 strategies, the first of which is to address 
lifestyle and the second to use medication. The first ap-
proach is the most physiologic, the least expensive, but is 
also the most difficult to implement. The second approach, 
which should help patients who failed the first approach, is 
at the advanced clinical research stage. 
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as steatosis and that a weight loss  ≥ 9% was additionally as-
sociated with less hepatocyte ballooning, less inflamma-
tion and a decrease in non-alcoholic fatty liver disease 
(NAFLD) activity score. This was confirmed in a random-
ized controlled trial where there was a correlation between 
improvement of NAFLD activity score in the histology and 
the percentage of weight change  [3] . People, who achieved 
a mean weight reduction of 8.7 kg due to lifestyle interven-
tions during a 48-week period, could reduce their overall 
NASH activity score by  ≥ 3 points. Huang et al. [4] also 
showed an improvement in histology for NASH patients 
due to a 1-year dietary program.
 Physical activity reduces steatosis in patients with 
NAFLD  [5] even when it is not enough to change body 
weight  [6] or to improve ALT  [7] , but according to St. 
George et al. [8] , it does improve gamma GT significant-
ly. Hallsworth et al.  [9] also showed an improvement of 
steatosis in sedentary adults through resistance exercise, 
even at a level where it does not have an impact on body 
weight. In a study by Oh et al. [10] , 169 obese men were 
enrolled in a 3-week weight reduction program. Those 
with physical activity of >4 h per week not only had an 
improvement of the hepatic steatosis, they also showed an 
improvement of hepatocellular apoptosis and hepatic 
stiffness.
 With regards to diet, omega-3 polyunsaturated fatty 
acids have been suggested to improve steatosis and AST, 
but not ALT  [11] . In a phase II randomized controlled 
trial though, no significant effects of ethyl-eicosapentae-
noic acid on histologic features of NASH were reported 
 [12] . Monounsaturated fatty acids have been reported in 
a controlled randomized study over 8 weeks to improve 
liver fat significantly, which was measured by proton nu-
clear magnetic resonance spectroscopy in patients with 
type 2 diabetes  [13] . Regarding the benefit of a Mediter-
ranean diet with a high consumption of monounsatu-
rated fatty acids, Ryan et al. [14] performed a random-
ized crossover study, which also demonstrated a decrease 
in liver fat and an improvement in insulin sensitivity. 
Machado et al. [15] found out that trans- and saturated 
fatty acids correlate with oxidative stress markers such as 
4-hydroxynonenal. In a rather provocative study, Kecha-
gias et al. [16] placed 18 healthy individuals on a high 
caloric fast food-based diet for 4 weeks. They gained 6.4 
kg and most of them had abnormal ALT at the end of the 
study. This clarifies the negative effects of excessive nu-
trition.
 Where sodas are concerned, fructose reduces the sati-
ety sensation; it is taken up into hepatocytes where it in-
creases lipogenesis as well as the production of reactive 
oxygen species and reduces lipid oxidation  [17] . Addi-
tionally, fructose has been shown to promote fibrosis as 
well as inflammation and hepatocyte ballooning in sub-
jects older than 48 years  [18] .
 There are more and more epidemiology studies show-
ing the beneficial effects of coffee. In a large survey and 
multivariate analysis, low caffeine intake was found to be 
an independent predictor for NAFLD, after adjustment 
for race, gender and metabolic syndrome components 
 [19] . Coffee consumption was lower in patients with 
more fibrosis, which allows the assumption of regular 
coffee having a protective role against NAFLD  [20] .
 Provocatively, no alcohol is worse than a little bit of 
alcohol. In a study conducted by the NASH Clinical Re-
search Network, it was discovered that NASH, fibrosis, 
ballooning, Mallory bodies and inflammation in histol-
ogy occurred more frequently in non-drinkers than mod-
erate drinkers  [21] .
 Smoking has also been associated with NAFLD  [22] 
and there are data showing that cannabis promotes liver 
fibrosis in patients with chronic hepatitis C  [23] . Finally, 
sleep duration is also important. Less than 5 h of sleep el-
evates the risk of NAFLD in middle-aged people signifi-
cantly and insufficient sleep has also been associated with 
an elevated risk for a fatty liver index  ≥ 60  [24] .
 Based on this evidence, it is clear that the first approach 
for patients with NASH is to review their habits and to 
discuss strategies with them that improve their lifestyles. 
Unfortunately, changing habits is difficult and even if it 
is the least expensive, the safest and the most effective 
treatment option for NASH, it is one of the least success-
ful in practice. Recommendations to perform exercise, eat 
differently and lose weight often remain wishful thinking.
 Drug Treatments 
 Antioxidants 
 In the past, antioxidative medication was discussed as 
a treatment of NASH. In randomized controlled trials, 
however, ursodeoxycholic acid was unconvincing as it 
was ineffective as monotherapy at the usual dose  [25] . 
Thiazolidinediones, which function as PPARγ agonists, 
did show positive effects in patients with NASH in ran-
domized controlled trials, but unfortunately, they result 
in significant weight gain  [26] .
 The systematic review of the network meta-analysis 
comparing the effectiveness of pharmacologic interven-
tions for NASH found that pentoxifylline, which is an in-
hibitor of TNF-α, may have an anti-fibrotic effect  [27] . A 
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meta-analysis confirmed possible advantages of pentoxi-
fylline in patients with NASH  [28] .
 A randomized controlled trial performed with non-
diabetic adults with NASH found that vitamin E for about 
2 years led to a significant improvement in histologic le-
sions  [29] . These results were duplicated in a pediatric 
trial  [30] , showing less hepatocellular ballooning in chil-
dren who were treated with vitamin E. Singh et al. [27] 
also reported a positive effect on ballooning by vitamin E. 
In a pooled analysis, it was suggested that vitamin E might 
also have a positive effect on histology in patients with 
diabetes and NASH (K. Kowdley et al. AASLD 2015, Ab-
stract 107). However, they could neither confirm an as-
sociation between vitamin E and changes in serum lipids 
nor an association with cardiac events. In other trials, 
however, vitamin E has been reported to be associated 
with cardiovascular events  [31] . This is an issue in pa-
tients with NASH since they are already at risk of cardio-
vascular events. In addition, the extended follow-up of 
the SELECT trial demonstrated a significant association 
between vitamin E and an increased risk of developing 
prostate cancer among healthy men  [32] . These aspects 
unfortunately decrease the attractiveness of an otherwise 
inexpensive, safe, well-tolerated and (probably) effective 
NASH treatment. It emphasizes the need for further trials 
on vitamin E, especially on its efficacy in diabetic patients 
as well as other possible treatments for NASH.
 Transcription Factor Agonists 
 Obeticholic acid is a semi-synthetic bile acid analog 
and a ligand for the farnesoid X receptor (FXR)  [33] . 
When bound to the FXR, it suppresses bile acid synthesis 
from cholesterol as well as hepatic lipid synthesis  [34] . It 
increases peripheral clearance of VLDL and accelerates 
reverse cholesterol transport  [34 ,  35] . In a randomized 
controlled trial  [36] , obeticholic acid (25 mg/day) was 
given to patients with NASH for 72 weeks. Eight centers 
in the US participated. The trial was halted when an in-
terim analysis based on 140 of the 280 planned end of 
treatment biopsies found superiority of obeticholic acid 
compared with placebo for the primary outcome. The 
primary outcome was determined by a decrease in 
NAFLD activity score of 2 points without worsening of 
fibrosis. This was met by 45% of patients on obeticholic 
acid compared with 21% in the placebo group. Moreover, 
a greater number of patients assigned to obeticholic acid 
had an improvement in fibrosis, hepatocellular balloon-
ing, steatosis and lobular inflammation. The mean change 
in NAFLD activity score was greater in patients treated 
with obeticholic acid. There was a significant reduction 
in the liver tests (such as ALAT, ASAT and γ-GT) except 
for alkaline phosphatase. Obeticholic acid treatment was 
also associated with weight loss. However, in patients 
with NASH, obeticholic acid led to higher cholesterol, 
higher LDL and decreased HDL cholesterol. Moreover, 
pruritus occurred in 23% of patients treated with obeticho-
lic acid as compared with only 6% in the placebo group. 
Therefore, the long-term safety of obeticholic acid needs 
to be addressed for further clarification.
 Elafibranor is a dual PPARα and PPARδ agonist. This 
drug has been tested in an international, phase II, random-
ized controlled trial [39]. It enrolled patients with a NAFLD 
activity score >3 from a large number of centers (n = 56) in 
Europe and the US. In an intention-to-treat analysis using 
the protocol definition of the primary end point, the study 
was negative. Using a new definition of the primary end 
point as a resolution of NASH without worsening of fibro-
sis, the result was statistically significant; 12% of patients in 
the placebo group achieved this new primary end point 
and 19% in the elafibranor group. The effect was stronger 
in patients with a NAFLD activity score >4 and in those 
with fibrosis. Importantly, this drug had beneficial effects 
on lipids with improvement of triglycerides, decrease in 
total cholesterol, decrease in non-HDL cholesterol and in-
crease in HDL cholesterol. Furthermore, an improvement 
in insulin sensitivity was detected, suggesting that elafibra-
nor may be safe in patients with NASH. Clearly, a larger 
study needs to duplicate these findings.
 Other Targets 
 Other targets might be considered in the treatment of 
patients with NASH. Hepatocellular apoptosis is impor-
tant for the progression of fibrosis. Anti-apoptotic drugs 
might prove useful in the treatment of NASH. Emricasan 
targets apoptosis through inhibition of caspases, and it is 
currently being evaluated in non-cirrhotic patients with 
NASH  [37] . However, long-term safety of such suppres-
sion of apoptosis needs to be evaluated, as cancer is the 
second most frequent cause of death in NASH patients.
 Patients with NASH are at risk of developing cirrhosis, 
which comes from deposition of fibrotic tissues in the liv-
er. Therapeutic strategies aimed at preventing fibrosis 
might also work in patients with NASH. Simtuzumab is 
an antibody against lysine oxidants and its efficacy is cur-
rently being tested  [37] . As an anti-fibrotic treatment, it 
may have a place in the future NASH treatment algorithm.
 Some chemokine ligands and their receptors, such as 
CCR2 and CCR5, are upregulated during NASH, which 
results in liver inflammation, fibrosis and steatosis  [38] . 
Cenicriviroc is a dual antagonist of CCR2 and CCR5, 
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which is currently being tested  [37] . By targeting chemo-
kines, this approach may also have potential in the treat-
ment of NASH.
 Conclusion 
 What the field desperately needs is a positive defini-
tion of NASH. NASH implies that alcohol has been ex-
cluded as a cause of the disease and that one has a histol-
ogy showing the typical lesions of the disease. It is crucial 
that we better understand the pathophysiologic mecha-
nisms underlying this disease in order to have a positive 
non-invasive definition, which will allow the selection of 
more homogenous groups of treatments as well as better 
definitions of end points for clinical trials.
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